Regeneron Pharmaceuticals Inc. buy Piper Sandler
Summary
This prediction is currently active. The prediction for Regeneron Pharmaceuticals Inc. disappoints with a performance of -11.75%. This prediction currently runs until 23.08.25. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 1.112% | 1.112% |
iShares Core DAX® | 1.164% | 1.549% |
iShares Nasdaq 100 | 0.118% | 0.969% |
iShares Nikkei 225® | 1.124% | -1.120% |
iShares S&P 500 | 0.479% | 1.068% |
Comments by Piper_Sandler for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren